Showing 5921-5930 of 6766 results for "".
- Indiana Becomes First 'SUNucated' State in 2018https://practicaldermatology.com/news/indiana-becomes-first-sunucated-state-in-2018/2457826/The Indiana Academy of Dermatology (IAD), with a grant from the American Society for Dermatologic Surgery Association (ASDSA), helped successfully pass legislation to ensure students are protected from the dangers of UV rays while
- Researchers Assess Tools to Measure QoL Impact of Skin Conditionshttps://practicaldermatology.com/news/researchers-assess-tools-to-measure-qol-impact-of-skin-conditions/2457827/Boston University School of Medicine researchers have set out to find the best tool to measure the impact of skin coniditons on patients' quality of life. Several dermatology and disease-specific tools have been developed to measure the impact of skin disease including the widel
- White Paper: It's Time to Start Prescribing Biosimilarshttps://practicaldermatology.com/news/white-paper-its-time-to-start-prescribing-biosimilars/2457843/The American College of Rheumatology’s new white paper, “The Science Behind Biosimilars — Entering a New Era of Biologic Therapy,
- New Recommendations Aim to Minimize Biotin Interference in Clinical Immunoassayshttps://practicaldermatology.com/news/new-recommendations-aim-to-minimize-biotin-interference-in-clinical-immunoassays/2457842/As the popularity of biotin has grown, so has the incidence of this vitamin interfering with critical medical tests, and now a review in The Journal of Applied Laboratory Medicine provides expert recommendat
- Novartis' Xolair Recommended in New Global Chronic Urticaria Guidelinehttps://practicaldermatology.com/news/novartis-xolair-recommended-in-new-global-chronic-urticaria-guideline/2457849/A new global guideline on chronic urticaria (CU) recommends Xolair (omalizumab), indicated as add-on therapy for the treatment of chronic spontaneous urticaria (CSU), for patients who are not responding to antihistamines. Xolair is the only licensed treatment option for CSU, a type of CU, for pat
- Dermira: Two Phase 3 Trials Evaluating Olumacostat Glasaretil in Patients with Acne Vulgaris Did Not Meet Co-Primary Endpointshttps://practicaldermatology.com/news/dermira-two-phase-3-trials-evaluating-olumacostat-glasaretil-in-patients-with-acne-vulgaris-did-not-meet-co-primary-endpoints/2457852/Dermira, Inc.'s investigational treatment olumacostat glasaretil (formerly DRM01) did not meet the co-primary endpoints in its two Phase 3 pivotal trials (CLAREOS-1 and CLAREOS-2) in patients ages nine years and older with moderate-to-severe acne vulgaris. “We are surprised and
- Mandy Moore, Garnier Team Up for Beauty Product Recyclinghttps://practicaldermatology.com/news/mandy-moore-garnier-team-up-for-beauty-product-recycling/2457854/Nearly half of Americans don’t recycle their beauty and personal care products, which is why they account for a significant amount of landfill waste, and This Is Us star Mandy Moore, #GarnierGirl and brand ambassador, is teaming up with Garnier and DoSomething.org to kick off the seco
- Skin Microbiome May Protect Against Skin Cancerhttps://practicaldermatology.com/news/skin-microbiome-may-protect-against-skin-cancer/2457857/Beneficial skin bacteria may protect against skin cancer, according to a new study in Science Advances. “We have identified a strain of Staphylococcus epidermidis, common on healthy human skin, that exerts a selective ability to inhibit the growth of some cancers,” sa
- SkinCeuticals US Taps Christina Fair as New GMhttps://practicaldermatology.com/news/skinceuticals-us-taps-christina-fair-as-new-gm/2457861/Christina (Tina) Fair is the new General Manager at SkinCeuticals US. Tina joins the US team from the SkinCeuticals DMI, where she has been the Vice President of Global Marketing since 2015. During her time in the DMI, Tina led the development o
- Burt's Bees Nature-Based Sensitive Skin Regimen Trumps Dermatologist-recommended Regimenhttps://practicaldermatology.com/news/burts-bees-nature-based-sensitive-skin-regimen-trumps-dermatologist-recommended-regimen/2457860/Burt's Bees nature-based sensitive line outperformed a dermatologist-recommended synthetic control regimen in a study of 120 people with clinically diagnosed sensitive skin from rosacea, atopic dermatitis/eczema, or cosmetic intolerance. The nat